Lymphoma Clinical Research
NEWLY DIAGNOSED LYMPHOMA
IRB# 041-03 Microarray Analysis of Patients with Diffuse Large B-Cell Lymphoma treated with CHOP/Rituximab
RELAPSED LYMPHOMA
IRB# 001-09 Phase II Trial of Non-myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response
IRB# 028-09 A Phase II Multicenter, single-arm, open-label study to determine the efficacy and safety of single-agent, lenalidomide (Revlimid®) in patients with Mantle Cell Non-Hodgkin's Lymphoma who have relapsed or progressed after treatment with Bortezomib or are refractory to bortezomib (Protocol CC-5013-MCL-001).
IRB# 219-09 A Phase 2 Mulit-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
IRB# 229-05 Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin's Lymphoma
IRB# 244-07 A Phase I/II Study of Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (BMS Protocol 180129)
IRB# 357-08 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients with Advanced Hematological Malignancies
IRB# 415-08 Phase I/II Dose-Escalation Study of the Pan-Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma
IRB# 441-08 A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients with Hematologic Malignancies
IRB# 442-07 A Phase 1/2a Open-label Study of Sequential Pralatrexate and Gemcitabine with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Lymphoproliferative Malignancies (Protocol PDX-009)
IRB# 533-08 Phase II, Multicenter, Simon Two-Stage Study of R788 in Patients with Relapsed or Refractory T-Cell Lymphoma
Updated: 11/20/2009 |